copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Telitacicept – Application in Therapy and Current Clinical Research Telitacicept is an innovative drug being studied in clinical trials for various autoimmune conditions This article summarizes the current research on Telitacicept’s potential to treat diseases like lupus, IgA nephropathy, and vasculitis by targeting B cells and reducing harmful antibody production
The Latest Progress in the Application of Telitacicept in Autoimmune . . . In March 2021, telitacicept, the world’s first dual target three-channel biologic, was approved in China for the treatment of SLE and is currently in clinical trials exploring multiple indications for other autoimmune diseases
Comparative efficacy and safety of different recommended doses of . . . The findings of this meta-analysis provide compelling evidence that the combination of telitacicept with standard therapy offers superior efficacy in the treatment of SLE compared to placebo or other biologics such as belimumab, when used in conjunction with standard treatment protocols
POS0535 COMPARISON OF TELITACICEPT AND BELIMUMAB IN PATIENTS WITH SLE Belimumab and telitacicept represent two biological agents recently approved for management of patients with active and refractory SLE Belimumab is a humanized monoclonal antibody of the immunoglobulin G1 lambda subtype (IgG1λ) that selectively targets and neutralizes B lymphocyte stimulator (BLyS), thereby inhibiting its role in autoimmune
Telitacicept in Systemic Lupus Erythematosus - ICH GCP Blocking the interaction of BLyS and APRIL with their cell membrane receptors (TACI, B-cell maturation antigen (BCMA), and B-cell activating factor receptor (BAFF-R) would inhibit B cell proliferation and maturation, suppresses immune responses and may alleviate autoimmune symptoms
Efficacy and safety of telitacicept in patients with SLE: Results from . . . Treatment with telitacicept (160 mg weekly) demonstrated favorable clinical outcomes and an acceptable safety profile in patients with moderate to severe SLE Telitacicept obtained its first approval in China in 2021 for the treatment of patients with active SLE
Exploring Telitacicept for Neurological Autoimmune Disorders: A Case . . . Due to pre-existing blood glucose concerns, the patient declined high-dose corticosteroid pulse therapy After thorough discussion of alternative options, including intravenous immunoglobulin, plasma exchange, and rituximab, the patient opted for subcutaneous telitacicept at a dose of 160 mg weekly
Good efficacy achieved by telitacicept, corticosteroids and . . . Telitacicept, corticosteroids and immunosuppressants are effective in the treatment of SLE combined with MOG-AD Dear Editor, SLE can infrequently manifest as myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) when involving the nervous system [1]
Prospective analysis of B cell subset dynamics following telitacicept . . . Combining telitacicept with standard therapy induced significant changes in B cell subsets and clinical markers in SLE patients The reduction in naive and transitional B cells, along with the restoration of Breg cell, suggests a potential positive influence on immunoregulatory capacity